Alx Oncology Holdings Inc SEC Filings

ALX Oncology (ALXO) reported Q3 2025 results highlighted by lower operating expenses and a smaller loss. Operating expenses were $22.5 million versus $32.6 million a year ago, driven by research and development of $17.4 million and general and administrative of $5.1 million. Net loss was $22.1 million, or $0.41 per share, compared with $30.7 million, or $0.58 per share, in Q3 2024.

Liquidity and balance sheet: Cash, cash equivalents and investments totaled $66.5 million as of September 30, 2025. Net cash used in operating activities was $65.2 million for the nine-month period. The company recorded a $3.2 million impairment in 2025 related to a planned sublease of a Palo Alto facility. Term loan balances were $4.3 million current and $5.8 million non-current. Management believes existing capital resources will fund operations for at least twelve months after the statements are issued.

Pipeline update: An exploratory analysis from the ASPEN‑06 gastric/GEJ study identified CD47 overexpression as a predictive biomarker in patients with retained HER2 expression, with reported outcomes including 65.0% ORR vs 26.1%, 25.5 vs 8.4 months median DOR, and improvements in PFS and OS for Evo‑TRP versus TRP.

ALX Oncology Holdings Inc. reported that it issued a press release announcing its financial results for the third quarter and full year ended September 30, 2025. The press release is furnished as Exhibit 99.1.

The company furnished this information under Item 2.02. The materials, including Exhibit 99.1, are not deemed “filed” and are not subject to Section 18 liability, nor incorporated by reference unless expressly stated.

ALX Oncology (ALXO) reported an insider equity award. On October 14, 2025, the company granted its SVP, Finance and CAO an employee stock option for 140,000 shares of common stock at a $1.70 exercise price, recorded as a grant at $0 price and held directly.

The option vests in two steps: one‑third on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the transaction, 140,000 derivative securities were beneficially owned.

ALX Oncology Holdings (ALXO)198,750 employee stock options on 10/14/2025 with an exercise price of $1.7 per share and an expiration date of 10/14/2035. The grant was recorded at a price of $0 for the derivative security, indicating an award rather than a purchase.

The vesting schedule splits the award into two tranches: one-third vests on April 30, 2026, and the remaining two-thirds vest on October 31, 2026. Following the transaction, the filing lists 198,750 derivative securities beneficially owned, held directly.

ALX Oncology Holdings Inc. (ALXO) reported an insider equity grant. The company’s Chief Executive Officer and Director received an employee stock option for 597,500 shares at an exercise price of $1.70 on October 14, 2025, expiring on October 14, 2035.

Vesting is staged: one‑third vests on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the grant, 597,500 derivative securities were beneficially owned, held directly.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 2,707,151 shares of ALX Oncology Holdings Inc. common stock, representing 5.1% of the class. The filing states the shares are held by entities subject to voting control and investment discretion of Millennium and related managers, and that the reporting persons do not claim sole ownership.

The statement is filed on a Schedule 13G, indicating a passive investment intent rather than an attempt to change control; a joint filing agreement among the three reporting persons is attached as an exhibit. The disclosure clarifies voting and disposition split as 0 shares sole power and 2,707,151 shares shared power.

ALX Oncology Holdings Inc. insider grant summary: Director Barbara Klencke was granted a stock option to buy 300,000 shares of ALX common stock at a $1.05 exercise price, with a transaction date of 09/17/2025 and an expiration date of 09/16/2035. The option is exercisable in tranches and is held directly.

The award vests in three installments: one-third on 09/17/2025, one-third on 01/31/2026 and the final one-third on 06/30/2026. The Form 4 was submitted on behalf of the reporting person by an attorney-in-fact.

ALX Oncology Holdings (ALXO) Form 4: Chief Executive Officer and director Jason Lettmann made open-market purchases of the issuer's common stock on 09/16/2025 and 09/17/2025. He acquired a total of 92,233 shares at weighted average prices of $1.066 and $1.0805 respectively. Following the transactions, the reporting person beneficially owned 305,121 shares. The filing discloses that the reported prices are weighted averages from multiple transactions within stated price ranges and that additional breakdowns are available on request. The Form 4 was signed by an attorney-in-fact on 09/18/2025.

ALX Oncology Holdings Inc. (ALXO) Chief Financial Officer Shantharam Harish reported a purchase of 75,000 shares of the company on 08/18/2025. The reported price is a weighted average of $0.7787 per share, with individual trade prices ranging from $0.6823 to $0.9234; the filer agrees to provide a breakdown of quantities at each price upon request. Following the transaction the reporting person beneficially owns 75,000 shares directly. The Form 4 was signed by an authorized representative on 08/20/2025.